Severe cardiac arrythmia on cisapride.
(1) Cisapride prolongs the QT interval and can cause torsades de pointes and ventricular tachycardia. (2) Cases of cardiac arrhythmia and death have occurred, even in the absence of underlying factors such as high doses and interactions with enzyme-inhibiting drugs (especially macrolide antibiotics, HIV protease inhibitors and antifungal imidazoles). (3) Cisapride was withdrawn from the market in the United States on 14 July 2000 and in Canada on 7 August 2000. We recommend that this measure should be applied worldwide.
D000328:Adult; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D002170:Canada; D002675:Child, Preschool; D020117:Cisapride / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D004335:Drug and Narcotic Control; D005602:France; D006801:Humans; D014481:United States
D020117:Cisapride